Associated Papers
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
39516321 (PubMed )
Supplement: 44276_2024_49_MOESM4_ESM.xlsx › supplementary_table_2
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM et al.
Nature Communications, 2023
Yeast-based evolutionary modeling of androgen receptor mutations and natural selection.
Zhang H et al.
Plos Genetics, 2022
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients.
Lallous N et al.
Cancers, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Tukachinsky H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M et al.
Ebiomedicine, 2020
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM et al.
The Oncologist, 2020
Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer.
Moses M et al.
Oncotarget, 2020
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T et al.
Scientific Reports, 2019
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N et al.
Genome Biology, 2016
Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men.
Robins DM
Molecular and Cellular Endocrinology, 2012
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
Steinkamp MP et al.
Cancer Research, 2009
Select a paper to view details